Pharma BD Deal Intelligence
ArQule paid ~$84M in stock for Camitro's ADMET modeling tech, never commercialized it, and shut the acquired operations within two years.
Full analysis, sources & comparables →ArQule completed its acquisition of Camitro, adding an integrated platform of predictive ADME/Tox modeling technologies for the design of pharmaceutical drug…
ArQule (Woburn, MA) acquired privately-held Camitro (Menlo Park, CA / Cambridge, UK), an in silico ADMET modeling company, for ~$85M closing value (3.4M shares…
ArQule completed a $95M merger with Camitro Corporation as the initial major step in CEO Stephen Hill's pivot from chemistry services to biopharmaceutical drug…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
ArQule acquired Camitro Corporation, an in silico ADME/Tox modeling company, in a stock-and-cash merger valued at ~$95M (announced; ~$85M at close: 3.4M ArQule shares + $1.7M cash). The deal integrated predictive ADMET into ArQule's parallel-synthesis discovery engine as CEO Stephen Hill pivoted from chemistry services toward drug discovery; ArQule ultimately could not commercialize the technology, leading to site closures and layoffs.
ArQule paid ~$84M in stock for Camitro's ADMET modeling tech, never commercialized it, and shut the acquired operations within two years.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ArQule Inc. / Camitro Corporation (this deal) | 2001 | $95M | 11 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals